CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory Disease
CincyTech is proud to announce its investment in Clarametyx Biosciences,a Columbus-based clinical-stage biotechnology company pioneeringimmune-enabling solutions to address bacterial biofilm-related chronicrespiratory diseases. This strategic investment will support Clarametyx’s continued development of its lead candidate, CMTX-101, a novel monoclonal antibody therapy targeting persistent infections in cystic fibrosis (CF)patients.